Somatropin Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL
Reference Brands: Genotropin (EU), Norditropin (EU/India)
Category:
Women's Health
Somatropin is available in injection (prefilled syringe)
and strengths such as 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Somatropin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Somatropin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production or secretion of growth hormone (GH) from the pituitary gland. Growth hormone plays a vital role in normal growth, metabolism, and overall body development. When the body does not produce enough GH, it can lead to growth failure in children and a range of metabolic and physical changes in adults. Globally, childhood growth hormone deficiency is estimated to affect approximately 1 in 4,000 to 10,000 children, while prevalence rates may vary by region. Adult growth hormone deficiency is less common but still represents an important endocrine disorder requiring proper diagnosis and management.
GHD is typically classified into two main types: childhood-onset growth hormone deficiency (CO-GHD) and adult-onset growth hormone deficiency (AO-GHD). Childhood-onset cases may be congenital, acquired, or idiopathic. Congenital GHD is usually associated with genetic abnormalities that affect the synthesis of growth hormone or the function of growth hormone–releasing hormone receptors. Acquired GHD may occur due to tumors affecting the pituitary gland or hypothalamus, surgical procedures, radiation therapy, brain injuries, infections such as meningitis, or other damage to the brain.
In adults, growth hormone deficiency often develops as a result of pituitary tumors, medical treatments affecting the pituitary region, or as a continuation of untreated childhood-onset GHD. In some cases, GHD occurs alone, while in others it may be associated with deficiencies of additional pituitary hormones. Early diagnosis and appropriate treatment are important to manage symptoms, support normal growth in children, and improve metabolic health and quality of life in affected individuals.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing